KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

Frank Kullmann, Esther Endlicher, Robert Stöhr et al.|Oncology|2011

Cited by 46